Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
For instance, SIRT7 has been identified as a key player in the pathogenesis of immune-mediated intestinal inflammation, specifically in inflammatory bowel disease (IBD)
Learn fundamentals - how to reconstitute peptides , bacteriostatic water guide , what are peptides
In the present study, we show that dietary supplementation with CoQ 10 H 2 significantly reduced white adipose tissue content and improved the function of brown adipose tissue by regulating expression of lipid metabolism-related factors in KKAy mice, a model of obesity and type 2 diabetes